Dimitrios Goundis is an Executive Board Member at Kither Biotech and brings over 30 years of experience in the life science and biotech sector, in senior management roles, and participated in 2 IPOs (NASDAQ in 2000 and SWX in 2005) and a number of financial and business transactions.
He was a member of the founding team of Exacis Inc, a cell therapy & immuno-oncology company as Chief Business Officer (CBO), from 2020 till its acquisition by Eterna Bio (NASDAQ:ERNA) in May 2023.
Between 2016 and 2020 he was CEO of MaxiVAX S.A., a private clinical stage Swiss Immuno-oncology company, which transitioned from preclinical development to Phase II.
From 2009 and 2015, he worked for The Medicines Company (NASDAQ: MDCO) in the US, Germany and Switzerland, as Senior Vice President (SVP), including Head of Research, Head of Business Development (EU) and Global Head of R & D. MDCO was acquired by Novartis in 2019 for $9.6B.
He was with Speedel (SWX:SPPN) in Switzerland, from its start in 2000 until its acquisition by Novartis in 2008 for $1B, as Managing Director of its subsidiary Speedel Experimenta and Chief Operating Officer (COO).
Prior to this he held senior project management positions at The Medicines Company (until its IPO in 2000) and F. Hoffman-La Roche in Basel.
Dimitrios was awarded a PhD in Biochemistry from the University of Oxford (UK), and following that, spent 2 years as a PostDoc scientist at the Basel Institute for Immunology.
He also holds a BSc (Hons) in Chemistry with Biochemistry from the University of London (UK), and a Certificate in Investment Management from the London Business School (UK).
He has published a number of scientific papers, in high impact journals including Nature.